Références :
1. Monographie de BEPREVE. Bausch & Lomb Incorporated. 22 juillet 2016.
2. Abelson MB et coll. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: A phase III, single-center, prospective,
randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children. Clin Ther 2009;31:1908–21.
3. Données internes, Bausch & Lomb Incorporated, 2017.
